# Pediatric Condition-Medication Reference

Evidence-based medication recommendations by condition with authoritative source citations.

## How to Use This Reference

1. Look up the clinical condition
2. Identify first-line and alternative medications
3. Use dosing from [dosing-guidelines.md](dosing-guidelines.md)
4. Query RxNorm for SCD codes using the lookup script
5. **Always cite the source** in your output

---

## Gastrointestinal Conditions

### Crohn's Disease
**Source**: NASPGHAN Clinical Practice Guidelines for Pediatric IBD (2019); ECCO-ESPGHAN Guidelines

| Line | Medication | Indication | Source Citation |
|------|------------|------------|-----------------|
| 1st | Prednisone/Prednisolone | Induction, moderate-severe | NASPGHAN 2019 |
| 1st | Exclusive Enteral Nutrition | Induction, alternative to steroids | ECCO-ESPGHAN 2020 |
| 2nd | Sulfasalazine | Mild colonic disease | NASPGHAN 2019 |
| 2nd | Methotrexate | Maintenance, steroid-sparing | NASPGHAN 2019 |
| 2nd | Azathioprine/6-MP | Maintenance | NASPGHAN 2019 |
| 3rd | Infliximab | Moderate-severe, biologic | NASPGHAN 2019 |
| 3rd | Adalimumab | Moderate-severe, biologic | NASPGHAN 2019 |

### Ulcerative Colitis
**Source**: NASPGHAN Clinical Practice Guidelines (2019)

| Line | Medication | Indication | Source Citation |
|------|------------|------------|-----------------|
| 1st | Mesalamine (5-ASA) | Mild-moderate | NASPGHAN 2019 |
| 1st | Prednisone | Moderate-severe induction | NASPGHAN 2019 |
| 2nd | Azathioprine/6-MP | Maintenance | NASPGHAN 2019 |
| 3rd | Infliximab | Refractory/severe | NASPGHAN 2019 |

### Gastroesophageal Reflux Disease (GERD)
**Source**: NASPGHAN/ESPGHAN GERD Guidelines (2018)

| Line | Medication | Indication | Source Citation |
|------|------------|------------|-----------------|
| 1st | Omeprazole | Erosive esophagitis | NASPGHAN 2018 |
| 1st | Lansoprazole | Erosive esophagitis | NASPGHAN 2018 |
| 2nd | Ranitidine* | Mild symptoms | NASPGHAN 2018 |

*Note: Ranitidine withdrawn from market; use famotidine as alternative

---

## Respiratory Conditions

### Asthma (Acute Exacerbation)
**Source**: GINA 2023; NAEPP EPR-4 Guidelines

| Line | Medication | Indication | Source Citation |
|------|------------|------------|-----------------|
| 1st | Albuterol (nebulized) | Bronchodilation | GINA 2023 |
| 1st | Ipratropium | Severe exacerbation, add-on | GINA 2023 |
| 1st | Prednisolone/Prednisone | Systemic corticosteroid | GINA 2023 |
| 2nd | Magnesium sulfate IV | Severe, refractory | NAEPP EPR-4 |

### Asthma (Maintenance - Step Therapy)
**Source**: GINA 2023

| Step | Medication | Age Group | Source Citation |
|------|------------|-----------|-----------------|
| 1-2 | Fluticasone ICS | 4+ years | GINA 2023 |
| 1-2 | Budesonide ICS | 6 months+ | GINA 2023 |
| 3 | Fluticasone/Salmeterol | 4+ years | GINA 2023 |
| 3 | Montelukast | 6 months+ | GINA 2023 |
| 4-5 | Add Tiotropium | 6+ years | GINA 2023 |

### Community-Acquired Pneumonia (CAP)
**Source**: IDSA/PIDS Pediatric CAP Guidelines (2011, reaffirmed)

| Line | Medication | Indication | Source Citation |
|------|------------|------------|-----------------|
| 1st | Amoxicillin | Outpatient, typical | IDSA/PIDS 2011 |
| 1st | Amoxicillin-clavulanate | Outpatient, if resistance | IDSA/PIDS 2011 |
| 2nd | Azithromycin | Atypical suspected | IDSA/PIDS 2011 |
| 2nd | Ceftriaxone | Inpatient | IDSA/PIDS 2011 |

---

## Infectious Disease

### Acute Otitis Media (AOM)
**Source**: AAP Clinical Practice Guidelines (2013)

| Line | Medication | Indication | Source Citation |
|------|------------|------------|-----------------|
| 1st | Amoxicillin | First-line | AAP 2013 |
| 1st | Amoxicillin (high-dose) | Severe, <2 years | AAP 2013 |
| 2nd | Amoxicillin-clavulanate | Treatment failure | AAP 2013 |
| 2nd | Cefdinir | Penicillin allergy (non-severe) | AAP 2013 |
| 3rd | Ceftriaxone IM | Treatment failure | AAP 2013 |

### Streptococcal Pharyngitis
**Source**: IDSA Guidelines (2012); AAP Red Book

| Line | Medication | Indication | Source Citation |
|------|------------|------------|-----------------|
| 1st | Penicillin V | First-line | IDSA 2012 |
| 1st | Amoxicillin | First-line (better taste) | IDSA 2012 |
| 2nd | Cephalexin | Penicillin allergy (non-severe) | AAP Red Book |
| 2nd | Azithromycin | Penicillin allergy (severe) | IDSA 2012 |

### Urinary Tract Infection (UTI)
**Source**: AAP UTI Guidelines (2011, reaffirmed 2016)

| Line | Medication | Indication | Source Citation |
|------|------------|------------|-----------------|
| 1st | Cephalexin | Outpatient, oral | AAP 2011 |
| 1st | Amoxicillin-clavulanate | Outpatient, oral | AAP 2011 |
| 1st | TMP-SMX | Outpatient (if susceptible) | AAP 2011 |
| 2nd | Ceftriaxone | Inpatient, IV | AAP 2011 |

---

## Allergic Conditions

### Allergic Rhinitis
**Source**: ARIA Guidelines; AAP

| Line | Medication | Indication | Source Citation |
|------|------------|------------|-----------------|
| 1st | Cetirizine | Antihistamine | ARIA 2020 |
| 1st | Loratadine | Antihistamine | ARIA 2020 |
| 1st | Fluticasone nasal | Intranasal steroid | ARIA 2020 |
| 2nd | Montelukast | Add-on therapy | ARIA 2020 |

### Anaphylaxis
**Source**: WAO Anaphylaxis Guidelines (2020)

| Line | Medication | Indication | Source Citation |
|------|------------|------------|-----------------|
| 1st | Epinephrine IM | First-line, life-saving | WAO 2020 |
| 2nd | Diphenhydramine | Adjunct, urticaria | WAO 2020 |
| 2nd | Methylprednisolone | Adjunct, prevent biphasic | WAO 2020 |

---

## Pain/Fever

### Fever/Mild Pain
**Source**: AAP Fever Guidelines; WHO

| Line | Medication | Indication | Source Citation |
|------|------------|------------|-----------------|
| 1st | Acetaminophen | Fever, pain | AAP 2011 |
| 1st | Ibuprofen | Fever, pain (>6 months) | AAP 2011 |

---

## Source Abbreviations

| Abbreviation | Full Name |
|--------------|-----------|
| AAP | American Academy of Pediatrics |
| NASPGHAN | North American Society for Pediatric Gastroenterology, Hepatology and Nutrition |
| ESPGHAN | European Society for Paediatric Gastroenterology Hepatology and Nutrition |
| ECCO | European Crohn's and Colitis Organisation |
| GINA | Global Initiative for Asthma |
| NAEPP | National Asthma Education and Prevention Program |
| IDSA | Infectious Diseases Society of America |
| PIDS | Pediatric Infectious Diseases Society |
| ARIA | Allergic Rhinitis and its Impact on Asthma |
| WAO | World Allergy Organization |
| WHO | World Health Organization |
